Novacyt provides an R&D update on its initial molecular products pipeline

R&D Strategy Update PR ENGLISH

Paris, France and Cambridge, UK – 5th September 2016 – Novacyt (ALTERNEXT: ALNOV), an international clinically focused diagnostics company, today provides a Research and Development (R&D) update following the completion of the acquisition of Primerdesign in May 2016. The integration of Primerdesign is progressing well, in line with the strategic objectives and management expectations defined at the time of the acquisition. Novacyt has now identified its initial molecular diagnostic targets for the clinical testing market, with the first assay expected to be launched in H1 2017.